Open tender · Germany · Contract notice
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff PEG-Epoetin beta, (OBO) ATC B03XA03 für die Zeit 01.02.2025 - 31.01.2027
DAK-Gesundheit in Germany is inviting bids for “Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff PEG-Epoetin beta, (OBO) ATC B03XA03 für die Zeit…”. Bids close on 4 December 2026. To qualify, bidders need at least one similar completed work.
The work
Non-exclusive discount agreement for PEG-Epoetin beta (ATC B03XA03) from 01.02.2025 to 31.01.2027
- Agreement to DAK-Gesundheit's contractual terms and prescribed discounts
Key facts
- Evaluation
- No formal evaluation method specified
- Submission
- Online, on the e-procurement portal
What it takes to qualify
Worth a closer look
- The tender is described as a non-exclusive discount agreement, not a standard public procurement
- Submission via email to a specific department, not through a formal portal
- No explicit mention of financial capacity or experience requirements
Experience
- At least 1 similar work — No specific experience requirement mentioned
Certifications and registrations
GST registration (optional)No mention of GST registration
PAN registration (optional)No mention of PAN registration
EPF registration (optional)No mention of EPF registration
ESIC registration (optional)No mention of ESIC registration
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- AngebotsschreibenOffer letter to be submitted via email
- Vertrag mit Namen oder FirmenstempelContract acknowledging DAK-Gesundheit terms and discounts
- Anlagen 1 und 2 zum VertragFilled contract annexes, with Annex 2 as Excel file
- Eigenerklärung zur Abwesenheit von AusschlusskriterienDeclaration that no exclusion criteria under §§ 123 and 124 GWB apply